1-6 of 6
Frank Fiebig
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1 -Mutated AML - the SAL/AMLCG Vincent Trial

Lydia Kretschmer, Leo Ruhnke, Christoph Schliemann, Lars Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, Christoph Schmid, Maher Hanoun, Tim Sauer, Klaus H Metzeler, Kerstin Schäfer-Eckart, Mathias Hänel, Martina Crysandt, Paul Jäger, Stefan W. Krause, Christine Dierks, Stefan Klein, Nadia Maguire, Lukas Peter Frenzel, Veit L. Buecklein, Frank Fiebig, Anna Harig, Christian Thiede, Moritz Middeke, Richard Dillon, Claudia D Baldus, Hubert Serve, Uwe Platzbecker, Karsten Spiekermann, Wolfgang Hiddemann, Martin Bornhäuser, Richard F. Schlenk, Carsten Müller-Tidow, Christoph Röllig
Journal: Blood
Blood (2024) 144 (Supplement 1): 1527.1.
https://doi.org/10.1182/blood-2024-198164
Published: 2024
Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Leo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, Matthias Stelljes, Lars Fransecky, Björn Steffen, Martin Kaufmann, Andreas Burchert, Andreas Rank, Maher Hanoun, Alexander Höllein, Sabrina Kraus, Mathias Hänel, Kerstin Schäfer-Eckart, Annett Haake, Frank Fiebig, Sven Zukunft, Jan Moritz Middeke, Désirée Kunadt, Johannes Schetelig, Malte von Bonin, Maximilian Alexander Röhnert, Uta Oelschlägel, Friedrich Stölzel, Claudia D Baldus, Hubert Serve, Martin Wermke, Martin Bornhäuser, Christoph Röllig
Journal: Blood
Blood (2023) 142 (Supplement 1): 160.
https://doi.org/10.1182/blood-2023-184445
Published: 2023
Journal Articles

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Christoph Röllig, Björn Steffen, Christoph Schliemann, Jan-Henrik Mikesch, Nael Alakel, Regina Herbst, Mathias Haenel, Richard Noppeney, Maher Hanoun, Martin Kaufmann, Zdenek Racil, Kerstin Schäfer-Eckart, Tim Sauer, Andreas Neubauer, Claudia D. Baldus, Jolana Mertova, Edgar Jost, Dirk Niemann, Jan Novak, Stefan W. Krause, Sebastian Scholl, Andreas Hochhaus, Gerhard Held, Tomáš Szotkowski, Christoph Schmid, Andreas Rank, Lars Fransecky, Michael Kramer, Frank Fiebig, Annett Haake, Friedrich Stoelzel, Johannes Schetelig, Jan Moritz Middeke, Uwe Platzbecker, Christian Thiede, Carsten Müller-Tidow, Wolfgang E. Berdel, Hubert Serve, Gerhard Ehninger, Jiří Mayer, Martin Bornhaeuser
Journal: Blood
Blood (2022) 140 (Supplement 1): 523–525.
https://doi.org/10.1182/blood-2022-157126
Published: 2022
Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Christoph Röllig, Lars Fransecky, Maher Hanoun, Björn Steffen, Sabrina Kraus, Christoph Schliemann, Annett Haake, Frank Fiebig, Sven Zukunft, Nael Alakel, Jan Moritz Middeke, Martin Bornhaeuser, Friedrich Stoelzel, Johannes Schetelig, Leo Ruhnke, Michael Kramer, Malte Von Bonin, Maximilian Alexander Röhnert, Uta Oelschlägel, Claudia D. Baldus, Hubert Serve, Martin Wermke
Journal: Blood
Blood (2022) 140 (Supplement 1): 3327–3328.
https://doi.org/10.1182/blood-2022-159897
Published: 2022
Journal Articles

Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

Christoph Röllig, Christoph Schliemann, Jan-Henrik Mikesch, Lars Fransecky, Claudia D. Baldus, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Sebastian Scholl, Ulf Schnetzke, Kerstin Schäfer-Eckart, Knut Wendelin, Martin Wermke, Manja Reimann, Frank Fiebig, Theresa Kretschmann, Friedrich Stoelzel, Nael Alakel, Martin Bornhäuser
Journal: Blood
Blood (2021) 138 (Supplement 1): 2324.
https://doi.org/10.1182/blood-2021-150069
Published: 2021
Journal Articles

Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Christoph Röllig, MD MSC, Björn Steffen, MD, Nael Alakel, MD, Regina Herbst, MD, Richard Noppeney, MD, Maher Hanoun, MD PhD, Zdenek Racil, MD PhD, Kerstin Schäfer-Eckart, MD, Alwin Krämer, MD, Andreas Neubauer, Professor Dr, Claudia D Baldus, MD, Christoph Schliemann, Prof., MD, Martin Kaufmann, MD, Jolana Mertova, Edgar Jost, Dirk Niemann, MD, Jan Novak, Stefan W Krause, Sebastian Scholl, Gerhard Held, Professor Dr, Stefani B. Parmentier, Tomáš Szotkowski, MD PhD, Pavel Zak, MD, Andreas Rank, PD Dr, Maxi Wass, MD, Sebastian Buske, Michael Kramer, Frank Fiebig, Annett Haake, Johannes Schetelig, MDMSc, Uwe Platzbecker, Christian Thiede, MD, Carsten Müller-Tidow, MD, Wolfgang E. Berdel, Prof., MD, Hubert Serve, MD PhD, Gerhard Ehninger, MD, Jiri Mayer, Martin Bornhäuser, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–3.
https://doi.org/10.1182/blood-2020-140246
Published: 2020